International
Available Domestic
U.S Domestic
Available Domestic
Dragon Pharma
Dragon Pharma Mazdutide 10 mg - Oxyntomodulin Dual Agonist Vial
Injection · 10 mg/ml · vial
In stock · ships within 24h
Out of stock
$180.00
Dragon Pharma Mazdutide 10 mg is an oxyntomodulin analogue peptide and a dual GLP-1 and glucagon agonist in a lyophilised research vial. It carries the same receptor pair as survodutide on a different peptide backbone, with a longer measured half-life.
Each vial is GMP-manufactured and HPLC-verified, with a Certificate of Analysis on file. Reconstitute with bacteriostatic water. Mazdutide 10 mg for sale with U.S. and international shipping.
Shipping
Not available in this combination
Discreet plain packaging
Worldwide reship guarantee
Crypto & card accepted
Product overview
Dragon Pharma Mazdutide 10 mg - GLP-1 and Glucagon Dual Agonist
Dragon Pharma Mazdutide 10 mg supplies the dual GLP-1 and glucagon receptor agonist peptide as a lyophilised research vial. Mazdutide is built on the oxyntomodulin backbone, the gut hormone that carries both incretin and glucagon activity naturally, and it remains an investigational peptide with no approved label. Buy mazdutide from a GMP manufacturer with independent testing and a Certificate of Analysis on file per batch.
- Mazdutide 10 mg per lyophilised research vial
- Oxyntomodulin analogue - dual GLP-1 and glucagon agonist
- Reference half-life about 8 days at 16 mg in a 2025 phase 1 study
- GMP-manufactured, HPLC-verified, COA on file per batch
How Mazdutide Works
Oxyntomodulin is released by the gut after a meal and acts on two receptors, so mazdutide keeps that dual character in one peptide: GLP-1 receptor activation slows gastric emptying and increases satiety signalling, while glucagon receptor activation raises energy expenditure. That is the same receptor pair used by Survodutide, on a different backbone. The single-agonist comparison is Semaglutide, and the three-receptor comparison is Retatrutide.
Research Amounts and Handling
No dose is approved for this vial, so every figure is research practice. A 2025 phase 1 study described a half-life of about 8 days at 16 mg, which is the basis for weekly subcutaneous dosing, and phase 1b studied 9 mg and 10 mg. Because an eight-day half-life outlasts the dosing interval, accumulation is expected and laboratory planning works on steady state. Reconstitute the 10 mg vial with bacteriostatic water: 2 ml gives 5 mg per ml and 1 ml gives 10 mg per ml. Store the powder at 2-8 C away from light and the solution refrigerated.
Quality & Authenticity
Every batch is produced under GMP conditions and checked by independent HPLC, with the Certificate of Analysis held for the batch. Nausea, vomiting, diarrhoea or constipation dominate the reported profile, appetite can fall sharply, and injection site reactions are the usual local effect. As with every peptide in this family, Tirzepatide included, appetite suppression overlaps across mechanisms, so materials are not added together in one protocol.
For laboratory research only. Consult a healthcare professional before use.
Specifications
| Trade Name | Mazdutide 10 mg |
| Generic Name | Mazdutide (oxyntomodulin analogue) |
| Manufacturer | Dragon Pharma |
| Dosage | 10 mg per lyophilised vial |
| Package | 1 vial of powder for reconstitution |
| Drug Class | Dual GLP-1 and glucagon receptor agonist (research peptide) |
| Administration | Reconstitute with bacteriostatic water, subcutaneous injection |
| Reference Half-Life | About 8 days at 16 mg in a 2025 phase 1 study |
| Shipping | International and U.S. domestic options |
Stacks
Consult a healthcare professional before any cycle. Doses are common community protocols.
FAQ
Before you ask
Questions, answered
It is mazdutide, an oxyntomodulin analogue peptide that activates the GLP-1 and glucagon receptors, sold as a lyophilised 10 mg research vial. It is an investigational material with no approved label and no human dose, so it is intended for laboratory work. It shares its receptor pair with survodutide but is a different molecule.
Oxyntomodulin is a natural gut hormone with activity at two receptors, and mazdutide reproduces that duality. GLP-1 receptor activation slows gastric emptying and increases satiety signalling; glucagon receptor activation raises energy expenditure and changes hepatic fuel handling. The combination is why the peptide is grouped with dual and triple agonists rather than with single-incretin products.
A 2025 phase 1 study described a half-life of about 8 days at a 16 mg dose, which is long enough to support weekly subcutaneous dosing. Because the half-life exceeds the interval, the peptide accumulates over the first weeks, so laboratory planning accounts for steady state. The value was measured in the investigational programme and is not a property published for this vial.
No human dose is approved for this vial. Phase 1b studied 9 mg and 10 mg, and the long half-life was measured at 16 mg, so research amounts span a wide range rather than one figure. Reconstituting the 10 mg vial with 2 ml of bacteriostatic water gives 5 mg per ml, which keeps a mid-range amount inside a practical syringe volume.
Nausea, vomiting, diarrhoea or constipation are the common reported effects, appetite can fall far enough to reduce food intake, and injection site reactions are the usual local effect. Gallbladder events and pancreatitis are class warnings carried by incretin peptides generally. No long-term human safety data exist for a reconstituted research vial of this kind.
Yes. The 10 mg vial is listed on this page with international and U.S. domestic shipping options, and the price charged matches the option you select. Orders are dispatched after payment confirmation. The product is sold strictly for laboratory research and carries no approved human dose or prescription status.
No reviews yet
Be the first to share your experience with Dragon Pharma Mazdutide 10 mg - Oxyntomodulin Dual Agonist Vial
Log in to write a reviewComplete the cycle
Stack it with
International
Available Domestic
International
International
Available Domestic